Toll-like receptors 3, 7, 8, and 9 in gastric cancer.
TLR3
TLR7
TLR8
TLR9
Toll-like receptors
gastric cancer
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
31
08
2022
accepted:
17
10
2022
pubmed:
23
10
2022
medline:
10
1
2023
entrez:
22
10
2022
Statut:
ppublish
Résumé
Toll-like receptors (TLRs) have been shown to have anti-tumor, pro-tumor, or even dual effects in cancer, and are thus potential prognostic biomarkers and immunotherapeutic targets. The present study aimed to evaluate associations between endosomal TLRs, namely TLR3, TLR7, TLR8, and TLR9, expression and clinicopathological variables and survival in gastric cancer. A total of 564 gastric adenocarcinoma patients were included in this retrospective cohort study. Samples and clinicopathological data were retrieved and organized into tissue microarray blocks. Protein expressions were detected by immunohistochemical staining. The patients were divided into low expression and high expression groups by median values of expression. Cox regression provided hazard ratios (HR) with 95% confidence intervals (CI), adjusted for confounders. Patients with high nuclear TLR3 expression had significantly poorer 5-year survival than the low nuclear TLR3 expression group in the univariable analysis (crude HR 1.31, 95% CI 1.07-1.60). With radically resected patients, poor prognosis was also seen in the multivariable analysis (adjusted HR 1.38, 95% CI 1.08-1.77). Cytoplasmic TLR3, TLR7, TLR8, and TLR9 were not associated with 5-year survival. In conclusion, high nuclear TLR3 expression seems to have prognostic impact in gastric cancer, while TLR7, TLR8, and TLR9 do not.
Substances chimiques
Toll-Like Receptor 3
0
Toll-Like Receptor 7
0
Toll-Like Receptor 9
0
Toll-Like Receptor 8
0
Toll-Like Receptors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
92-99Subventions
Organisme : Finnish Medical Foundation
Organisme : Finnish State Research Funding
Organisme : Orion Research Foundation
Organisme : Thelma Mäkikyrö Foundation
Organisme : Mary and Georg C. Ehrnroot Foundation
Organisme : Päivikki and Sakari Sohlberg Foundation
Organisme : The Finnish Cancer Foundation
Organisme : Finnish Cultural Foundation
Organisme : Vieno and Alli Suorsa Healthcare Foundation
Organisme : Sigrid Juselius Foundation
Informations de copyright
© 2022 Scandinavian Societies for Pathology, Medical Microbiology and Immunology.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5(12):1749-68.
Asplund J, Kauppila JH, Mattsson F, Lagergren J. Survival trends in gastric adenocarcinoma: a population-based study in Sweden. Ann Surg Oncol. 2018;25(9):2693-702.
Cui L, Wang X, Zhang D. TLRs as a promise target along with immune checkpoint against gastric cancer. Front Cell Dev Biol. 2021;8:611444.
Diakowska D, Nienartowicz M, Grabowski K, Rosińczuk J, Krzystek-Korpacka M. Toll-like receptors TLR-2, TLR-4, TLR-7, and TLR-9 in tumor tissue and serum of the patients with esophageal squamous cell carcinoma and gastro-esophageal junction cancer. Adv Clin Exp Med. 2019;28(4):515-22.
Braunstein MJ, Kucharczyk J, Adams S. Targeting toll-like receptors for cancer therapy. Target Oncol. 2018;13(5):583-98.
El-Omar EM, Ng MT, Hold GL. Polymorphisms in toll-like receptor genes and risk of cancer. Oncogene. 2008;27(2):244-52.
Shcheblyakov DV, Logunov DY, Tukhvatulin AI, Shmarov MM, Naroditsky BS, Gintsburg AL. Toll-like receptors (TLRs): the role in tumor progression. Acta Theriol. 2010;2(3):21-9.
Moss SF, Malfertheiner P. Helicobacter and gastric malignancies. Helicobacter. 2007;12(Suppl 1):23-30.
Cuzzubbo S, Mangsbo S, Nagarajan D, Habra K, Pockley AG, Mcardle SEB. Cancer vaccines: adjuvant potency, importance of age, lifestyle, and treatments. Front Immunol. 2021;11:615240.
Schmoll H, Wittig B, Arnold D, Riera-Knorrenschild J, Nitsche D, Kroening H, et al. Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014;140(9):1615-24.
Ishihara M, Tono Y, Miyahara Y, Muraoka D, Harada N, Kageyama S, et al. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Cancer Immunol Immunother. 2020;69(4):663-75.
Murphy A, Kelly RJ. Immunotherapy in upper GI malignancies. Curr Treat Options Oncol. 2015;16(5):20.
Kasurinen A, Hagström J, Laitinen A, Kokkola A, Böckelman C, Haglund C. Evaluation of toll-like receptors as prognostic biomarkers in gastric cancer: high tissue TLR5 predicts a better outcome. Sci Rep. 2019;9(1):12553.
Fernandez-Garcia B, Eiró N, González-Reyes S, González L, Aguirre A, González LO, et al. Clinical significance of toll-like receptor 3, 4, and 9 in gastric cancer. J Immunother. 2014;37(2):77-83.
Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open-source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.
Castano-Rodríguez N, Kaakoush NO, Mitchell HM. Pattern-recognition receptors and gastric cancer. Front Immunol. 2014;5:336.
Huhta H, Helminen O, Lehenkari PP, Saarnio J, Karttunen TJ, Kauppila JH. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma. Oncotarget. 2016;7(17):23658-67.
Helminen O, Huhta H, Lehenkari PP, Saarnio J, Karttunen TJ, Kauppila JH. Nucleic acid-sensing toll-like receptors 3, 7 and 8 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma. OncoImmunology. 2016;5(5):01-25.
Muresan XM, Culig Z, Soucek K, Bouchal J. Toll-like receptor 3 in solid cancer and therapy resistance. Cancer. 2020;12(11):3227.
Bianchi F, Milione M, Casalini P, Centonze G, Le Noci VM, Storti C. Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients. Sci Rep. 2019;9(1):14288.
Helminen O, Huhta H, Leppänen J, Kauppila JH, Takala H, Lehenkari PP, et al. Nuclear localization of Toll-like receptor 5 in Barrett's esophagus and esophageal adenocarcinoma is associated with metastatic behavior. Virchows Arch. 2016;469(4):465-70.
Huhta H, Helminen O, Kauppila JH, Salo T, Porvari K, Saarnio J, et al. The expression of toll-like receptors in normal human and murine gastrointestinal organs and the effect of microbiome and cancer. J Histochem Cytochem. 2016;64(8):470-82.